Results of General Meeting

Publication of circular and notice of general meeting

Appointment of CEO, amendments to the Financing terms, termination of the Formal Sale Process and proposed Delisting

Board Change and Updates on Financing and Formal Sale Process 

Issue of New Ordinary Shares and Total Voting Rights

Change in Registered Office

Issue of New Ordinary Shares and Total Voting Rights

Sensyne Health Interim Results

Successful Completion of Financing and Notice of General Meeting

Update on Trading, Formal Sale Process, Commercial Progress and Proposed Financing

Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

Sensyne Health and Cambridge University Hospitals NHS Foundation Trust Sign Strategic Research Agreement

Response to disciplinary notice

Strategic update and commencement of Formal Sale Process

Test-To-Go System powered by MagnifEye receives European regulatory certification

Financial results for the 12 months ended 30 April 2021 and Operational Update

Sensyne launches SENSIGHT – a real world patient data analytics platform for the life science and healthcare industries

Sensyne Health and Great Ormond Street Hospital partner to apply ethical AI to drive research in childhood disease

Sensyne Health and Sentara Healthcare Form New Partnership for Ethical Data Sharing and Design of New Clinical Algorithms

Sensyne Health to conduct its first multi-omics AI drug discovery project in partnership with Oxford University

Sensyne grows medical research dataset to 60 million patients

Appointment of Chief Scientific Officer

Sensyne Health wins Comparably Awards for Best CEO for Women and Best Leadership Team

Sensyne Health Provides Strategic Update Including Exploring a Potential Dual-Listing on Nasdaq

Board Appointment

MagnifEye Production Contract with the UK’s Department of Health & Social Care

Sensyne Health Trading Update

Sensyne Health Signs Strategic Research Agreement with the Colorado Center for Personalized Medicine

Sensyne Health Signs First U.S. Strategic Research Agreement with St. Luke’s University Health Network

Sensyne Health and Phesi enter joint commercial development collaboration with a leading pharmaceutical company

Sensyne Health’s MagnifEye AI software product gains MHRA ‘Authorisation of Special Use’ in connection with DHSC COVID-19 Self-Test Lateral Flow Device

Sensyne Health and Royal Devon and Exeter NHS Foundation Trust sign Strategic Research Agreement

Agreement with the UK Department of Health & Social Care to pilot Sensyne Health’s MagnifEye™ technology for use with COVID-19 lateral flow diagnostic tests

Board changes

Syne-COV COVID prediction algorithm achieves UKCA mark status

Sensyne Health licenses MagnifEye technology to Excalibur Healthcare Services for use with lateral flow diagnostic tests

Sensyne Health announces the launch of its first operational AI algorithm for real-time hospital management of patients

Sensyne Health Interim Results

Sensyne Health and The Royal Wolverhampton NHS Trust sign Strategic Research Agreement

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

Completion of Fundraising and Strategic Collaboration with Phesi

Result of Open Offer

Tony Bourne to join as Independent Non-Executive Director

Sensyne Health launches first digital health product in the U.S.

Sensyne Health and Hampshire Hospitals NHS Foundation Trust sign Strategic Research Agreement

Sensyne Health achieves five million patient target set at IPO

Sensyne Health and Somerset NHS Foundation Trust sign Strategic Research Agreement

Sensyne Health appoints President, North America, to lead US expansion

Sensyne Health’s CVm-Health+ software application to facilitate rapid COVID-19 antigen testing study by the University of Oxford

Result of Annual General Meeting

Sensyne Health announces strategic partnership with Microsoft and co-development of cloud and machine learning capabilities

Statement from Sensyne Health

Sensyne Health and Milton Keynes University Hospital sign Strategic Research Agreement

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

Sensyne Health and NHS Greater Glasgow and Clyde sign data access agreement

Full Year Results

University of Oxford collaboration on Phase II clinical trial in care homes to prevent respiratory failure due to COVID-19

Holdings in company

Sensyne Health announces the UK launch of ‘SENSE™’ - a clinical algorithm engine, created in partnership with Microsoft

Sensyne Health announces development of ‘DBm-Health™’ a new software product for people with or at risk of diabetes

Clinical AI leader Sensyne Health launches CVm-Health™ ‘Good Neighbor’ app in the United States with support from Microsoft and Cognizant

Trading and Business Update

Sensyne Health announces launch of new BPm-Health™ remote monitoring system for the management of blood pressure in pregnancy in response to COVID-19 pandemic

Sensyne Health launches CVm-Health™ ‘Good Neighbour’ app

GDm-Health™ remote monitoring system made available free-of-charge during COVID-19 pandemic

Sensyne Health recognised for its impact in helping treat diabetes in pregnancy

Sensyne Health Interim Results

Sensyne Health enters into a research collaboration to apply AI for clinical trial design

Update Following General Election

NHS staff fears over multinational 'big tech' firms analysing patient data

Sensyne Health wins Healthtech Company of the Year award at 2019 European Lifestars Awards™

Sensyne Health names Cognizant and Agorai as partners for the launch and sale of its digital health software products in the U.S.

Sensyne Health Partners with Bayer on New UK Artificial Intelligence ‘LifeHub’ for Data-Driven Drug Discovery, Disease Detection and Diagnosis

Sensyne Health Maiden Full Year Results

Sensyne Health enters into a research collaboration with UK MHRA to validate digital health software algorithms

Sensyne Health signs major agreements with a Fortune 200 healthcare company and a data infrastructure specialist to launch and scale its digital health products in the U.S.

Annual Report and Accounts and Notice of Annual General Meeting

Sensyne Health Announces Related Party Transactions

Notice of Full Year Results

Sensyne Health signs collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using Clinical Artificial Intelligence

Sensyne Health welcomes EY report Realising the Value of Healthcare Data which highlights the potential of patient data to be used for healthcare innovation and economic benefit to the UK

Sensyne Health welcomes EY’s announcement on AI and blockchain to link healthcare reimbursement and actual patient outcomes

Sensyne Health, Evotec, OSI and the University of Oxford create new partnership called LAB10x to accelerate data-driven drug discovery powered by AI

Bayer joins Sensyne Health consortium working on national linked patient data capability for accelerating the discovery of new medicines

Sensyne Health signs agreement with Jefferson Health to evaluate the clinical and commercial potential of GDm-Health™ in the United States

Sensyne Health Maiden Interim Results 2018

Sensyne Health and George Eliot Hospital NHS Trust sign Strategic Research Agreement

Sensyne Health and the University of Oxford’s Big Data Institute to establish world-leading research alliance using data science and clinical AI for the patient-centred management and treatment of chronic disease

Sensyne Health and Wye Valley NHS Trust sign Strategic Research Agreement

Sensyne Health welcomes UK government announcement today endorsing the potential of analysing anonymised NHS patient data in an ethical way to improve patient care and accelerate medical research

Sensyne Health signs Strategic Advisory Services agreement with EY

Official product launch of GDm-Health™

Board Appointment: Professor Lionel Tarassenko Appointed as Non-Executive Director and Director of R&D

Sensyne Health licenses Privitar’s data privacy software

Sensyne Health welcomes and commits to new government code of conduct for data-driven health and care technologies

Sensyne Health plc Admission to trading on AIM and First Day of Dealings

Sensyne Health plc Placing and Proposed Admission to trading on AIM

Sensyne Health acquires digital health software product for the treatment of heart failure developed by The George Institute for Global Health at the University of Oxford and Oxford University Hospitals NHS Foundation Trust

Sensyne Health signs Strategic Research Agreement with Oxford University Hospitals NHS Foundation Trust